Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study

Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Natalie Brajanovski, BSc, Donald P Cameron, BSc, Gretchen Poortinga, PhD, Elaine Sanij, PhD, John Lim, PharmD, John Soong, MD FCAP, Nadine Hein, PhD, Emma Link, DPhil, Richard B Pearson, PhD, Ross Hannan, Grant A. McArthur, MBBS, PhD BSc, FRACP, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD

Blood (2017) 130 (Supplement 1): 3835.

https://doi.org/10.1182/blood.V130.Suppl_1.3835.3835

Published: 2017

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Hang Quach, MD, Simon Harrison, MD, Liam J. Fernyhough, MB, BS, BMedSci, Ross Alistair Henderson, PhD FRACP, FRCPA, Gillian Corbett, MDFRACP FRCPA, Peter Browett, MBChB, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Craig Underhill, MD, Paul Cannell, MD, Judith Trotman, MBChB, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince, MD

Blood (2015) 126 (23): 4236.

https://doi.org/10.1182/blood.V126.23.4236.4236

Published: 2015

Journal Articles

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J. Harrison, Hang Quach, Emma Link, John F. Seymour, David S. Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H. Miles Prince

Blood (2011) 118 (24): 6274–6283.

https://doi.org/10.1182/blood-2011-03-339879

Published: 2011

Includes: Supplemental data

Journal Articles

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Lisa Demosthenous, Glen Wiesner, PhD, Emma Link, PhD, David Alan Westerman, MBBS, FRACP, FRCPA, Neil Came, MBBS, FRACP, FRCPA, John F Seymour, MD, FRACP, PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2010) 116 (21): 2256.

https://doi.org/10.1182/blood.V116.21.2256.2256

Published: 2010

Journal Articles

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Sam A Ruell, RN, Miles Prince, MD, FRACP, FRCPA, Hang Quach, MBBS, FRACP, FRCPA, MD, Emma Link, PhD, Joanne Dean, Simon J. Harrison, MD, PhD

Blood (2010) 116 (21): 5037.

https://doi.org/10.1182/blood.V116.21.5037.5037

Published: 2010

Journal Articles

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

David Alan Westerman, MBBS, FRACP, FRCPA, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, MBBS, Linda Mileshkin, Emma Link, PhD, Alexander Dobrovic, H. Miles Prince

Blood (2010) 116 (21): 4046.

https://doi.org/10.1182/blood.V116.21.4046.4046

Published: 2010

NARROW

RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only